Thursday, June 6, 2013
Publication and contact
Epidermal growth factor receptor 3 (EGFR3;
Patient sample and mouse
studies identified oncogenic somatic mutations in ERBB3 that could
guide the use of HER2 and ErbB3 inhibitors. Whole-exome sequencing of 507
human primary tumor samples identified protein-altering somatic mutations in ERBB3
in 12% of gastric cancers, 11% of colon cancers and sporadically in other
types of cancer. In both mouse and human cell lines, ERBB3 mutations
plus ErbB2 expression promoted oncogenic transformation,
anchorage-independent growth and IL-3-independent cell survival. In a
mouse model for Erbb3 mutant leukemia, anti-ErbB3 mAbs or the
anti-HER2 mAb Herceptin
decreased disease severity and increased survival compared with a control
mAb. Next steps include conducting studies to further elucidate the
mechanisms by which mutant ERBB3 drives oncogenesis.
Inc. unit markets Herceptin to treat breast and gastric cancers
cancer through ErbB3, page 1).
Published online June 6, 2013
Patent and licensing status
Jaiswal, B.S. et al.
Cancer Cell; published online May 13, 2013;
Contact: Somasekar Seshagiri, Genentech Inc., South San
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]